kerendia trial | Effect of Finerenone on Chronic Kidney Disease Outcom

Keyword	CPC	PCC	Volume	Score	Length of keyword
kerendia trial	1.45	0.3	7208	26	14
kerendia	1.58	1	5595	18	8
trial	0.94	1	3587	41	5

Keyword	CPC	PCC	Volume	Score
kerendia trial	1.94	1	1203	43
kerendia free trial	1.3	0.1	2927	22
kerendia free trial coupon	0.48	1	2981	3
kerendia 30 day free trial	1.35	0.7	2907	79
kerendia free trial offer	1.56	0.4	692	82
kerendia 90 day free trial	0.1	0.2	8058	91
kerendia clinical trials	1.34	0.2	2500	76
kerendia free trial voucher	1.9	0.2	3672	43
kerendia free trial card	1.73	0.2	2104	87

Search Results related to kerendia trial on Search Engine

Effect of Finerenone on Chronic Kidney Disease Outcomes in …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2025845

WEBPublished October 23, 2020. N Engl J Med 2020;383: 2219 - 2229. DOI: 10.1056/NEJMoa2025845. VOL. 383 NO. 23. Abstract. Background. Finerenone, a nonsteroidal, selective mineralocorticoid receptor...

DA: 17 PA: 81 MOZ Rank: 41 Up or Down: Up

Cardiovascular Events with Finerenone in Kidney Disease and …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2110956

WEBAug 28, 2021 · In the FIGARO-DKD trial, finerenone therapy improved cardiovascular outcomes, as compared with placebo, in patients with type 2 diabetes who had stage 2 to 4 CKD with moderately elevated ...

DA: 70 PA: 88 MOZ Rank: 95 Up or Down: Up

FDA approves drug to reduce risk of serious kidney and heart
fda.gov

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease

WEBFDA has approved Kerendia (finerenone) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal hearts attacks, and hospitalization for heart failure...

DA: 73 PA: 31 MOZ Rank: 100 Up or Down: Up

FIGARO-DKD & FIDELIO-DKD Efficacy Data | KERENDIA® …
kerendiahcp.com

https://www.kerendiahcp.com/clinical-trial-data/efficacy-data

WEBIn the FIGARO-DKD trial of adult patients with CKD associated with T2D. KERENDIA: Proven to reduce the risk of CV events13*†. 2.1% ARR16 (95% CI: 0.4-3.8) NNT: 4716 (95% CI: 26-266) to prevent a primary composite endpoint event. at 42 months. View the FIGARO-DKD article published in NEJM here.

DA: 75 PA: 65 MOZ Rank: 16 Up or Down: Up

Bayer reports further positive results on Kerendia in CKD
clinicaltrialsarena.com

https://www.clinicaltrialsarena.com/news/bayer-reports-further-positive-results-on-kerendia-in-ckd/

WEBNov 6, 2023 · By GlobalData. In September 2023, Bayer added three investigator-sponsored Phase III clinical trials evaluating Kerendia for the treatment of heart failure. Kerendia generated €67m ($72.04m) worth of sales in Q2 2023, according to the company’s half-year report. GlobalData forecasts that sales of Kerendia will exceed …

DA: 72 PA: 62 MOZ Rank: 60 Up or Down: Up

Bayer to present new data on Kerendia™ (finerenone) from …
bayer.com

https://www.bayer.com/media/en-us/bayer-to-present-new-data-on-kerendia-finerenone-from-comprehensive-clinical-trial-program-in-chronic-kidney-disease-and-type-2-diabetes/

WEBBerlin, June 15, 2023 – Bayer will present new cardiorenal data from the comprehensive Kerendia™ (finerenone) clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) at the 60th European Renal Association (ERA) congress 2023.

DA: 25 PA: 83 MOZ Rank: 57 Up or Down: Up

Bayer to present new cardiorenal data from comprehensive Kerendia
bayer.com

https://www.bayer.com/media/en-us/bayer-to-present-new-cardiorenal-data-from-comprehensive-kerendia-finerenone-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes/

WEBBerlin, October 26, 2022 – Bayer will present new renal and cardiovascular (CV) data from the comprehensive Kerendia™ (finerenone) clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) at the American Society of Nephrology’s (ASN) Kidney Week 2022, from 1-6 November.

DA: 81 PA: 17 MOZ Rank: 89 Up or Down: Up

Bayer Extends Clinical Development Program for KERENDIA® …
businesswire.com

https://www.businesswire.com/news/home/20210920005126/en/Bayer-Extends-Clinical-Development-Program-for-KERENDIA%C2%AE-finerenone-With-Phase-III-Study-to-Investigate-Use-in-Patients-With-Nondiabetic-Chronic-Kidney-Disease

WEBSep 20, 2021 · KERENDIA – a nonsteroidal mineralocorticoid receptor antagonist (MRA) – was approved in the United States on July 9, 2021, to reduce the risk of sustained eGFR decline, end-stage kidney disease,...

DA: 26 PA: 32 MOZ Rank: 62 Up or Down: Up

Bayer to present new Kerendia™ (finerenone) data from …
bayer.com

https://www.bayer.com/media/en-us/bayer-to-present-new-kerendiatm-finerenone-data-from-comprehensive-clinical-trial-program-across-a-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes/

WEB03. June. 2022. |. 09:00 AM. Europe/Amsterdam. Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes. Summary.

DA: 36 PA: 98 MOZ Rank: 34 Up or Down: Up

Clinical Review - Finerenone (Kerendia) - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK594386/

WEBFinerenone was approved by the FDA on July 9, 2021, to be used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal MI, and hospitalization for heart failure in adult patients with CKD associated with T2D. 11 It was approved by the Australian Therapeutic Goods Administration on November 18, 2021 ...

DA: 100 PA: 78 MOZ Rank: 17 Up or Down: Up